FDA Releases Guidance for Electronic Submission of Postmarket Non-Expedited ICSRs

Summary

The Food and Drug Administration (FDA) has released a guidance document for the pharmaceutical industry on submitting adverse drug experience reports in electronic format, specifically for postmarket non-expedited individual case safety reports (ICSRs). The guidance aims to ensure compatibility with FDA's electronic submission requirements.